First Implant Completed in Pivotal Study of GORE® TAG® Thoracic Branch Endoprosthesis
Enrollment begins on new clinical study for the first device designed specifically for the endovascular treatment of aortic arch lesions
GORE® EXCLUDER® AAA Endoprosthesis Gore Completes Primary Enrollment for the Gore EXCLUDER® Iliac Branch Clinical Study
62 patients enrolled in US investigational device exemption clinical study to assess first complete, low-profile system for managing common iliac artery aneurysms or aorto-iliac aneurysms
GORE® EXCLUDER® Iliac Branch Endoprosthesis Is First Dedicated System of Its Kind Approved in Europe
First Successful Implants Completed in Italy and the United Kingdom, Providing Endovascular Repair to Iliac Arteries
First Patients Enrolled in Gore Thoracoabdominal Aortic Aneurysm Clinical Study
Device offers first and only complete “off-the-shelf” endovascular system specifically designed to treat aortic aneurysms involving visceral branch vessels
Gore Again Named One of the 100 Best Companies to Work For®
Every year since 1998: That’s how long W. L. Gore & Associates has appeared on the Fortune 100 Best Companies to Work For® list
GORE® EXCLUDER® Iliac Branch Endoprosthesis Exceeds 1,000 Implants Worldwide
Innovative system for managing common iliac artery aneurysms or aortoiliac aneurysms impacting lives around the world
GORE® C3 Delivery System Approved In Japan
System Enables Physicians and Interventionalists to Reposition GORE® EXCLUDER® AAA Endoprosthesis for Ideal Placement in Treating Abdominal Aortic Aneurysms
Gore Marks Two-Year Primary Endpoint Follow-up Milestone in Study of GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure
Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication
Gore Presents Astronaut and Scientist Mae C. Jemison, MD, as Keynote Speaker at Women in Vascular Leadership Luncheon
The pioneering Dr. Jemison, who flew aboard the Space Shuttle Endeavour, will address vascular surgeons at the 2014 SCVS symposium in Carlsbad, Calif.
Market-leading TEVAR Device is First to Surpass 100,000 Devices Distributed Worldwide
Proven, durable device leads the market, continues to impact lives